Christelle Sallès, Au bénéfice du doute - Les « notables de la ménopause » face aux risques du Traitement Hormonal Substitutif, Rapport de recherche pour la MiRe DREES, , 157 p. (lire en ligne), Annexe 2 - Mises sur le marché des traitements hormonaux de la ménopause [1948-2003] (page 142)
Curry, Whelpton, Schepper et Vranckx, « Kinetics of fluphenazine after fluphenazine dihydrochloride, enanthate and decanoate administration to man. », British Journal of Clinical Pharmacology, vol. 7, no 4, , p. 325–331 (PMID444352, PMCID1429660, DOI10.1111/j.1365-2125.1979.tb00941.x)
Driowo, Landgren, Stenström et Diczfalusy, « A comparison of the pharmacokinetic properties of three estradiol esters », Contraception, vol. 21, no 4, , p. 415–424 (PMID7389356, DOI10.1016/S0010-7824(80)80018-7)
Burke, Chen, Packer et Fuchs, « Young Women's Experiences With Subcutaneous Depot Medroxyprogesterone Acetate: A Secondary Analysis of a One-Year Randomized Trial in Malawi », Journal of Adolescent Health, vol. 67, no 5, , p. 700–707 (PMID32389457, DOI10.1016/j.jadohealth.2020.03.038)
Zhou, Walker, Ackermann et Olsen, « Effect of Manufacturing Variables and Raw Materials on the Composition-Equivalent PLGA Microspheres for 1-Month Controlled Release of Leuprolide », Molecular Pharmaceutics, vol. 17, no 5, , p. 1502–1515 (PMID32074448, DOI10.1021/acs.molpharmaceut.9b01188)
Lindenmayer, Glick, Talreja et Underriner, « Persistent Barriers to the Use of Long-Acting Injectable Antipsychotics for the Treatment of Schizophrenia », Journal of Clinical Psychopharmacology, vol. 40, no 4, , p. 346–349 (PMID32639287, DOI10.1097/JCP.0000000000001225, S2CID220412843)
Lindauer et Becker, « Insulin depot absorption modeling and pharmacokinetic simulation with insulin glargine 300 U/mL », Int. Journal of Clinical Pharmacology and Therapeutics, vol. 57, no 1, , p. 1–10 (PMID30369394, PMCID6298133, DOI10.5414/CP203269)
Jain, Karunakaran et Friedman, « Construction of a Photoactivated Insulin Depot », Angewandte Chemie International Edition, vol. 52, no 5, , p. 1404–1409 (PMID23208858, DOI10.1002/anie.201207264)
(en) Kennedy, « When and how to use long-acting injectable antipsychotics », Current Psychiatry, vol. 11, no 8, , p. 40–43 (lire en ligne)
(en) Carpenter et Wong, « Long-acting injectable antipsychotics: What to do about missed doses », Current Psychiatry, vol. 17, no 7, , p. 10–12, 14–19, 56 (lire en ligne)
(en) Kennedy, « When and how to use long-acting injectable antipsychotics », Current Psychiatry, vol. 11, no 8, , p. 40–43 (lire en ligne),
Priest et Smith, « Depot penicillin in the treatment of bacterial endocarditis. », Quarterly Bulletin. Northwestern University (Evanston, Ill.). Medical School, vol. 23, no 1, , p. 90–92 (PMID18109791, PMCID3802847)
Curry, Whelpton, Schepper et Vranckx, « Kinetics of fluphenazine after fluphenazine dihydrochloride, enanthate and decanoate administration to man. », British Journal of Clinical Pharmacology, vol. 7, no 4, , p. 325–331 (PMID444352, PMCID1429660, DOI10.1111/j.1365-2125.1979.tb00941.x)
Driowo, Landgren, Stenström et Diczfalusy, « A comparison of the pharmacokinetic properties of three estradiol esters », Contraception, vol. 21, no 4, , p. 415–424 (PMID7389356, DOI10.1016/S0010-7824(80)80018-7)
Mishell DR, « Pharmacokinetics of depot medroxyprogesterone acetate contraception. », The Journal of Reproductive Medicine, vol. 41, no 5 Suppl, mai1996, p. 381–90 (PMID8725700)
Burke, Chen, Packer et Fuchs, « Young Women's Experiences With Subcutaneous Depot Medroxyprogesterone Acetate: A Secondary Analysis of a One-Year Randomized Trial in Malawi », Journal of Adolescent Health, vol. 67, no 5, , p. 700–707 (PMID32389457, DOI10.1016/j.jadohealth.2020.03.038)
Zhou, Walker, Ackermann et Olsen, « Effect of Manufacturing Variables and Raw Materials on the Composition-Equivalent PLGA Microspheres for 1-Month Controlled Release of Leuprolide », Molecular Pharmaceutics, vol. 17, no 5, , p. 1502–1515 (PMID32074448, DOI10.1021/acs.molpharmaceut.9b01188)
Lindenmayer, Glick, Talreja et Underriner, « Persistent Barriers to the Use of Long-Acting Injectable Antipsychotics for the Treatment of Schizophrenia », Journal of Clinical Psychopharmacology, vol. 40, no 4, , p. 346–349 (PMID32639287, DOI10.1097/JCP.0000000000001225, S2CID220412843)
Lindauer et Becker, « Insulin depot absorption modeling and pharmacokinetic simulation with insulin glargine 300 U/mL », Int. Journal of Clinical Pharmacology and Therapeutics, vol. 57, no 1, , p. 1–10 (PMID30369394, PMCID6298133, DOI10.5414/CP203269)
Jain, Karunakaran et Friedman, « Construction of a Photoactivated Insulin Depot », Angewandte Chemie International Edition, vol. 52, no 5, , p. 1404–1409 (PMID23208858, DOI10.1002/anie.201207264)
« [https://sante.gouv.fr/fichiers/bo/2000/00-19/a0191324.htm Bulletin Officiel n�2000-19] », sur sante.gouv.fr (consulté le ) : « Benzo-Gynoestryl Retard 5 mg/1 ml (hexahydrobenzoate d'estradiol), solution injectable IM en ampoule de 1 ml (B/1) (laboratoires Roussel Diamant) »
Lindenmayer, Glick, Talreja et Underriner, « Persistent Barriers to the Use of Long-Acting Injectable Antipsychotics for the Treatment of Schizophrenia », Journal of Clinical Psychopharmacology, vol. 40, no 4, , p. 346–349 (PMID32639287, DOI10.1097/JCP.0000000000001225, S2CID220412843)